Abstract:Over the last decade, more than 300 phase I and phase II gene-based clinical trials have been conducted worldwide for the treatment of cancer and monogenic disorders. Lately, these trials have been extended to the treatment of AIDS and, to a lesser extent, cardiovascular diseases. There are 27 currently active gene therapy protocols for the treatment of HIV-1 infection in the USA. Preclinical studies are currently in progress to evaluate the possibility of increasing the number of gene therapy clinical trials for cardiopathies, and of beginning new gene therapy programs for neurologic illnesses, autoimmuno diseases, allergies, regeneration of tissues, and to implement procedures of allogeneic tissues or cell transplantation. In addition, gene transfer technology has allowed for the development of innovative vaccine design, known as genetic immunization. This technique has already been applied in the AIDS vaccine programs in the USA. These programs aim to confer protective immunity against HIV-1 transmission to individuals who are at risk of infection. Research programs have also been considered to develop therapeutic vaccines for patients with AIDS and generate either preventive or therapeutic vaccines against malaria, tuberculosis, hepatitis A, B and C viruses, influenza virus, La Crosse virus, and Ebola virus. The potential therapeutic applications of gene transfer technology are enormous. However, the effectiveness of gene therapy programs is still questioned. Furthermore, there is growing concern over the matter of safety of gene delivery and controversy has arisen over the proposal to begin in utero gene therapy clinical trials for the treatment of inherited genetic disorders. From this standpoint, despite the latest significant achievements reported in vector design, it is not possible to predict to what extent gene therapeutic interventions will be effective in patients, and in what time frame.

Progression and Application of HIV-1-derived Lentivectors

Recent Advances in Lentiviral Vectors for Gene Therapy.

Integrase-deficient lentivirus: opportunities and challenges for human gene therapy.

Application of Lentiviral Vectors in Genetic Engineering

Efficient gene transfer mediated by HIV-1-based defective lentivector and inhibition of HIV-1 replication

Lentivirus-Mediated Gene Transfer and Expression in Established Human Tumor Antigen-Specific Cytotoxic T Cells and Primary Unstimulated T Cells

[Application progress of CRISPR/Cas9 genome editing technology in the treatment of HIV-1 infection].

New Hope of Gene Therapy Results from Improvements of Lentiviral Vectors——Review

Lentiviral Delivery of Proteins for Genome Engineering

Advance in Gene Therapy of Tumors

Pseudotyped Lentiviral Vectors: Ready for Translation into Targeted Cancer Gene Therapy?

RNAi-inducing lentiviral vectors for anti-HIV-1 gene therapy

Gene Therapy Progress and Prospects: Nonviral vectors

Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy

Analysis of hepatic lentiviral vector transduction; implications on preclinical studies and clinical gene therapy protocols.

Analysis of hepatic lentiviral vector transduction; implications for preclinical studies and clinical gene therapy protocols

Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications

A novel inducible lentiviral system for multi-gene expression with human HSP70 promoter and tetracycline-induced promoter

Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications

Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: Implications for HIV gene therapy.

Advances in HIV Gene Therapy